Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer

Introduction: Multicenter, phase I study of concurrent and delayed nivolumab plus nab-paclitaxel/carboplatin in advanced non-small cell lung cancer (NSCLC). Methods: Chemotherapy-naive patients with advanced NSCLC (ineligible for potentially curative radiation or surgery) received nab-paclitaxel 100...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Oncol
Auteurs principaux: Goldman, Jonathan W., Waterhouse, David M., George, Ben, O'Dwyer, Peter J., Bhore, Rafia, Banerjee, Sibabrata, Lyons, Larry, Louis, Chrystal U., Ong, Teng Jin, Kelly, Karen
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2019
Sujets:
Oncology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6901975/
https://ncbi.nlm.nih.gov/pubmed/31850192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01256
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires